Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

By J. Forbes, Jack Cuzick, A. Buzdar, A. Howell, J. Tobias, M. Baum. The Lancet Oncology, 2008

652 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics

View Paper: https://www.semanticscholar.org/paper/e0eee54b3f1866b397bf6e28cc8c7f3a13edcce2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Jianmin Jiang
2. W. Shi
3. Yi-Sheng Sun
4. Zhi-yong Zhu
5. P. Yao
6. Hanping Zhu
7. Hangjing Lu
8. Fang Xu

Citations in the corpus

• Risk Factors and Preventions of Breast Cancer (2017, background): “Many trials such as the Italian Tamoxifen Anastrozole (ITA) trial, Intergroup Exemestane Study (IES), Austrian Breast and Colorectal Cancer Study Group (ABCSG-8), and the Breast International Group (BIG) 1-98 study have showed that in the adjuvant setting, AIs are more potent than TAM in reducing th”